D-Nome

About D-Nome

D-Nome is a health-tech startup utilizing cell-free synthetic biology to provide rapid and accurate molecular diagnostics. Their technology enables scalable diagnostic solutions, addressing the need for accessible and efficient testing in healthcare.

```xml <problem> Current molecular diagnostic methods often lack the speed, accuracy, and scalability needed for widespread and efficient testing, particularly in resource-limited settings. Traditional diagnostic techniques can be complex, time-consuming, and require specialized laboratory infrastructure. </problem> <solution> D-Nome is developing cell-free synthetic biology-based diagnostics to enable rapid and accurate molecular testing. Their technology aims to democratize molecular diagnostics by providing scalable solutions that can be deployed in various settings. The core technology, D-LAMP, is an enzyme mix that facilitates rapid and accurate diagnostic results. This approach simplifies the diagnostic process, potentially reducing the need for extensive laboratory equipment and skilled personnel. </solution> <features> - Cell-free synthetic biology platform for molecular diagnostics - D-LAMP enzyme mix for rapid and accurate results - Scalable diagnostic solutions suitable for diverse settings </features> <target_audience> The primary target audience includes healthcare providers, diagnostic kit manufacturers, and research institutions seeking accessible and efficient molecular diagnostic solutions. </target_audience> ```

What does D-Nome do?

D-Nome is a health-tech startup utilizing cell-free synthetic biology to provide rapid and accurate molecular diagnostics. Their technology enables scalable diagnostic solutions, addressing the need for accessible and efficient testing in healthcare.

Where is D-Nome located?

D-Nome is based in Hyderabad, Pakistan.

When was D-Nome founded?

D-Nome was founded in 2021.

How much funding has D-Nome raised?

D-Nome has raised $1.6M.

Location
Hyderabad, Pakistan
Founded
2021
Funding
$1.6M
Employees
6 employees
Investors
Ankur CapitalCampus FundEntrepreneurs First3i PartnersYourcampus Fund
DN

D-Nome

D-Nome is a health-tech startup utilizing cell-free synthetic biology to provide rapid and accurate molecular diagnostics. Their technology enables scalable diagnostic solutions, addressing the need for accessible and efficient testing in healthcare.

Hyderabad, PakistanFounded 202161K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 19 months ago

Funding

$1.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

EFII+1
Funding rounds are not available yet.

Founders

Product

Problem

Current molecular diagnostic methods often lack the speed, accuracy, and scalability needed for widespread and efficient testing, particularly in resource-limited settings. Traditional diagnostic techniques can be complex, time-consuming, and require specialized laboratory infrastructure.

Solution

D-Nome is developing cell-free synthetic biology-based diagnostics to enable rapid and accurate molecular testing. Their technology aims to democratize molecular diagnostics by providing scalable solutions that can be deployed in various settings. The core technology, D-LAMP, is an enzyme mix that facilitates rapid and accurate diagnostic results. This approach simplifies the diagnostic process, potentially reducing the need for extensive laboratory equipment and skilled personnel.

Target Audience

The primary target audience includes healthcare providers, diagnostic kit manufacturers, and research institutions seeking accessible and efficient molecular diagnostic solutions.

Features

  • Cell-free synthetic biology platform for molecular diagnostics
  • D-LAMP enzyme mix for rapid and accurate results
  • Scalable diagnostic solutions suitable for diverse settings
1
This profile is AI-generated and may contain inaccuracies.